MKMegan L. Kelly

Megan L. Kelly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Megan L. Kelly has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enhanced-Sampling Molecular Dynamics Recovers Rare Functional RNA Conformations Across Diverse Structural Contexts

    by Deng Li, Megan Ken

    Accurate determination of RNA conformational ensembles is essential for understanding RNA function and advancing RNA-targeted drug discovery, yet lowly-populated alternative states remain difficult to resolve with atomistic detail. A central constraint is that experimental refinement can only select conformations already present in the starting library, making library generation the limiting step. Using the HIV-1 trans-activation response element (TAR) as a model system, we benchmarked conventional MD (cMD) against the enhanced sampling methods Gaussian-accelerated MD (GaMD), replica-exchange Gaussian-accelerated MD (Rex-GaMD), replica-exchange with solute tempering (REST2), and temperature replica-exchange MD (T-REMD), as well as the structure-prediction based methods FARFAR2 and AlphaFold 3. Each library was refined against experimental residual dipolar couplings (RDC) and validated independently using ensemble-averaged QM/MM chemical shifts. We showed that T-REMD produced the most accurate ensemble by both measures, and its advantage tracked with broader, more continuous coverage of the interhelical conformational landscape. Broad temperature-range T-REMD also sampled conformations resembling excited state 1 (ES1) and the U23-A27-U38 base-triple, without requiring these states to be specified during library generation. More accurate ensembles further improved coverage of experimentally observed ligand-bound TAR conformations and enhanced ensemble-based virtual screening, linking structural accuracy to functional utility. The same workflow applied to the preQ 1 class I riboswitch and the UUCG tetraloop improved agreement with experimental data in both cases. Together, these results establish replica-exchange enhanced sampling, particularly T-REMD, as an effective strategy for constructing experimentally validated RNA ensembles and accessing conformations corresponding to rare functional substates. Graphical

  • Open Access

    Integrative in silico and in vitro screening of small molecules targeting RNA

    by Sabrina Toews, Megan Ken, Harald Schwalbe

    Targeting structured RNA elements with small molecules has emerged as a promising yet technically challenging strategy for antiviral drug discovery. Here, we present a comprehensive and experimentally validated workflow for the integrative in silico and in vitro screening of RNA‐binding small molecules. The approach is exemplified using conserved RNA elements from the SARS‐CoV‐2 genome, including the 5’‐terminal stem‐loop 1 and the programmed –1 ribosomal frameshift pseudoknot, but is broadly applicable to other structured RNAs. The workflow integrates high‐resolution RNA structural ensemble generation with virtual screening (VS) and nuclear magnetic resonance (NMR)‐based experimental validation. Conformational ensembles generated by fragment‐assembly approaches serve as targets for docking chemically diverse fragments and lead‐like libraries. Top‐ranked compounds are prioritized through consensus scoring and evaluated using ligand‐ and RNA‐observed NMR experiments to confirm binding, characterize interaction modes, and assess specificity. Such ranking allows for NMR‐guided fragment optimization, which enables systematic improvement of solubility, affinity, and selectivity through iterative medicinal chemistry in the pharmaceutical pipeline. Detailed procedures are provided for library preparation, ensemble‐based VS, hit validation, data interpretation, and progression toward functional assays, together with practical considerations, quality‐control parameters, and troubleshooting guidance to ensure reproducibility. By combining computational and experimental strategies that select for high‐specificity ligands within a unified framework, this set of protocols accelerates the discovery and optimization of RNA‐targeting small molecules and provides a scalable platform for RNA‐focused drug discovery. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1 : Target and library preparation for virtual screening Basic Protocol 2 : Ensemble‐based virtual screening of low‐molecular‐weight compounds against RNA targets Basic Protocol 3 : Comparative hit prioritization and selectivity filtering for RNA‐binding small molecules Basic Protocol 4 : Preparation of RNA samples for in vitro validation of small‐molecule binding Basic Protocol 5 : NMR‐based in vitro screening of RNA–small molecule interactions Support Protocol : Preparation of ligand stocks and NMR‐based quality control Basic Protocol 6 : Characterization and prioritization of validated RNA‐binding hits

  • Open Access

    Integrative In Silico and In Vitro Screening of Low Molecular Weight Compounds Targeting SARS‐CoV‐2 RNA Elements

    by Sabrina Toews, Betül Ceylan, Anna Wacker, Megan Ken, Harald Schwalbe

    An approach combining virtual and nuclear magnetic resonance (NMR)‐based screening is presented here to identify low molecular weight molecules (small molecules) targeting viral RNA elements from the SARS‐CoV‐2 genome. The so‐called high‐resolution RNA structural Fragment Assembly of RNA with Full‐Atom Refinement 2 (FARFAR2) ensembles of the conserved 5 ′ ‐terminal stem‐loop 1 (SL1) and the pseudoknot of the –1 programed frameshift element are used as targets for binding of small molecules of three different virtual libraries of compounds. The resulting hits predicted by virtual screening are probed for their binding to the two RNA elements by ligand‐ and target‐based NMR experiments. The results demonstrate that the integration of virtual and experimental NMR screening efficiently identifies RNA‐binding small molecules as start molecular entities to advance RNA‐targeted antiviral therapies in an efficient manner. The strategy does not only apply to SARS‐CoV‐2, but also provides a rapid, highly specific route to discovering therapeutics for other RNA‐based pathogens, highlighting the critical role of RNA structural data in enriching virtual drug discovery efforts.


  • Open Access

    Author Correction: RNA conformational propensities determine cellular activity

    by Megan L. Ken, Rohit Roy, Ainan Geng, Laura R. Ganser, Akanksha Manghrani, Bryan R. Cullen, Ursula Schulze-Gahmen, Daniel Herschlag, Hashim M. Al-Hashimi

  • RNA conformational propensities determine cellular activity

    by Megan L. Ken, Rohit Roy, Ainan Geng, Laura R. Ganser, Akanksha Manghrani, Bryan R. Cullen, Ursula Schulze-Gahmen, Daniel Herschlag, Hashim M. Al-Hashimi

    Cellular processes are the product of interactions between biomolecules, which associate to form biologically active complexes1. These interactions are mediated by intermolecular contacts, which if disrupted, lead to alterations in cell physiology. Nevertheless, the formation of intermolecular contacts nearly universally requires changes in the conformations of the interacting biomolecules. As a result, binding affinity and cellular activity crucially depend both on the strength of the contacts and on the inherent propensities to form binding-competent conformational states2,3. Thus, conformational penalties are ubiquitous in biology and must be known in order to quantitatively model binding energetics for protein and nucleic acid interactions4,5. However, conceptual and technological limitations have hindered our ability to dissect and quantitatively measure how conformational propensities affect cellular activity. Here we systematically altered and determined the propensities for forming the protein-bound conformation of HIV-1 TAR RNA. These propensities quantitatively predicted the binding affinities of TAR to the RNA-binding region of the Tat protein and predicted the extent of HIV-1 Tat-dependent transactivation in cells. Our results establish the role of ensemble-based conformational propensities in cellular activity and reveal an example of a cellular process driven by an exceptionally rare and short-lived RNA conformational state.


  • Open Access

    RNA conformational propensities determine cellular activity

    by Megan L. Kelly, Rohit Roy, Ainan Geng, Laura R. Ganser, Akanksha Manghrani, Bryan R. Cullen, Ursula Schulze-Gahmen, Daniel Herschlag, Hashim M. Al-Hashimi

    Cellular processes are the product of interactions between biomolecules, which associate to form biologically active complexes 1 . These interactions are mediated by intermolecular contacts, which if disrupted, lead to alterations in cell physiology. Nevertheless, the formation of intermolecular contacts nearly universally requires changes in the conformations of the interacting biomolecules. As a result, binding affinity and cellular activity crucially depend not only on the strength of the contacts, but also on the inherent propensities to form binding-competent conformational states 2,3 . Thus, conformational penalties are ubiquitous in biology and must be known in order to quantitatively model binding energetics for protein and nucleic acid interactions 4,5 . However, conceptual and technological limitations have hindered our ability to dissect and quantitatively measure how conformational propensities impact cellular activity. Here, we systematically altered and determined the propensities for forming the protein-bound conformation of HIV-1 TAR RNA. These propensities quantitatively predicted the binding affinities of TAR to the RNA-binding region of the Tat protein and predicted the extent of HIV-1 Tat-dependent transactivation in cells. Our results establish the role of ensemble-based conformational propensities in cellular activity and reveal an example of a cellular process driven by an exceptionally rare and short-lived RNA conformational state.


  • Open Access

    Understanding the characteristics of nonspecific binding of drug-like compounds to canonical stem–loop RNAs and their implications for functional cellular assays

    by Megan L. Kelly, Chia-Chieh Chu, Honglue Shi, Laura R. Ganser, Hal P. Bogerd, Kelly Huynh, Yuze Hou, Bryan R. Cullen, Hashim M. Al-Hashimi

    Identifying small molecules that selectively bind an RNA target while discriminating against all other cellular RNAs is an important challenge in RNA-targeted drug discovery. Much effort has been directed toward identifying drug-like small molecules that minimize electrostatic and stacking interactions that lead to nonspecific binding of aminoglycosides and intercalators to many stem–loop RNAs. Many such compounds have been reported to bind RNAs and inhibit their cellular activities. However, target engagement and cellular selectivity assays are not routinely performed, and it is often unclear whether functional activity directly results from specific binding to the target RNA. Here, we examined the propensities of three drug-like compounds, previously shown to bind and inhibit the cellular activities of distinct stem–loop RNAs, to bind and inhibit the cellular activities of two unrelated HIV-1 stem–loop RNAs: the transactivation response element (TAR) and the rev response element stem IIB (RREIIB). All compounds bound TAR and RREIIB in vitro, and two inhibited TAR-dependent transactivation and RRE-dependent viral export in cell-based assays while also exhibiting off-target interactions consistent with nonspecific activity. A survey of X-ray and NMR structures of RNA-small molecule complexes revealed that aminoglycosides and drug-like molecules form hydrogen bonds with functional groups commonly accessible in canonical stem–loop RNA motifs, in contrast to ligands that specifically bind riboswitches. Our results demonstrate that drug-like molecules can nonspecifically bind stem–loop RNAs most likely through hydrogen bonding and electrostatic interactions and reinforce the importance of assaying for off-target interactions and RNA selectivity in vitro and in cells when assessing novel RNA-binders.


  • Open Access

    Revealing the high propensity of RNAs to non-specifically bind drug-like small molecules

    by Megan L. Kelly, Chia-Chieh Chu, Honglue Shi, Laura R. Ganser, Hal P. Bogerd, Kelly Huynh, Yuze Hou, Bryan R. Cullen, Hashim M. Al-Hashimi

    Identifying small molecules that selectively bind a single RNA target while discriminating against all other cellular RNAs is an important challenge in RNA-targeted drug discovery. Much effort has been directed toward identifying drug-like small molecules that minimize electrostatic and stacking interactions that lead to non-specific binding of aminoglycosides and intercalators to a variety of RNAs. Many such compounds have been reported to bind RNAs and inhibit their cellular activities, however the ability of such compounds to discriminate against RNA stem-loops commonly found in the transcriptome has not been thoroughly assessed in all cases. Here, we examined the propensities of three drug-like compounds, previously shown to bind and inhibit the cellular activity of three distinct RNAs, to non-specifically bind two HIV-1 stem-loop RNAs: the transactivation response element (TAR) and stem IIB in the rev response element (RREIIB). All three compounds bound to TAR and RREIIB in vitro , and two inhibited TAR-dependent transactivation and RRE-dependent viral export in cell-based assays while also exhibiting substantial off-target interactions consistent with non-specific cellular activity. A survey of X-ray and NMR structures of RNA-small molecule complexes revealed that drug-like molecules form hydrogen bonds with functional groups commonly accessible in canonical stem-loop RNA motifs, much like aminoglycosides, and in contrast to ligands that specifically bind riboswitches. Our results support extending the group of non-selective RNA-binders beyond aminoglycosides and intercalators to encompass drug-like compounds with capacity for non-specific hydrogen-bonding and reinforce the importance of assaying for off-target interactions and RNA selectivity in vitro and in cells when assessing novel RNA-binders.